Hong Kong Stock Movement
CLOUDBREAK-B fell 16.79%. Based on recent key news:
<ol>
<li>
On December 10, CLOUDBREAK-B's wholly-owned subsidiary Cloudbreak USA successfully held a Phase 2 clinical trial meeting with the U.S. Food and Drug Administration, involving the clinical development of CBT-004. The meeting marked significant progress in the clinical development of CBT-004, paving the way for its entry into Phase 3 clinical research, new drug application, and commercialization. However, the market remains skeptical about the progress of the clinical trial and future uncertainties, leading to a decline in stock price.
</li>
<li>
On December 12, Zhitong Finance reported that CBT-004 is effective in alleviating conjunctival hyperemia, with effects visible as soon as 7 days after the first dose. Although the clinical trial results indicate good safety for the drug, investors still have concerns about its market potential and competitive environment, affecting stock performance.
</li>
<li>
On December 12, Economic Information Agency reported that while there has been progress in the clinical development of CBT-004, the market remains cautious about its commercialization prospects and the complexity of the regulatory approval process, leading to stock price fluctuations. The pharmaceutical industry's clinical trial risks are high and require attention.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Akeso, Inc. fell 6.67%. Based on recent key news:
<ol>
<li>
On December 11, Akeso, Inc. announced that the FDA approved its global multicenter Phase 3 trial to study the efficacy and safety of the innovative PD-1/CTLA-4 bispecific antibody cadonilimab in gastric cancer. This progress marks a significant advancement in innovative treatment methods; however, market uncertainty regarding trial results may lead to stock price fluctuations. Source: Akeso, Inc.
</li>
<li>
On December 12, Akeso, Inc. faces risks from industry competition and economic factors, including interest rate and exchange rate fluctuations, pharmaceutical industry regulation, and global healthcare cost control trends. These factors may affect the company's ability to forecast future market conditions. Source: Akeso, Inc.
</li>
<li>
On December 12, Akeso, Inc. aims to become a leading global biopharmaceutical company by developing first-class new drugs and providing affordable therapeutic antibodies through efficient R&amp;D innovation and integration of global resources. However, there is uncertainty in the market regarding its innovation capabilities and the continuous creation of commercial value. Source: Akeso, Inc. Industry competition is intensifying, and economic factors have a significant impact.
</li>
</ol>
BeiGene fell 7.35%. Based on recent key news:
<ol>
<li>
On December 15, BeiGene recorded large cross-trade transactions, with the stock price down 6.9% from the previous closing price, and the transaction amount reached HKD 879 million, with a net active sell of HKD 3.9122 million, indicating significant selling pressure on the stock. Source: Economic Information Agency
</li>
<li>
On December 12, the National Medical Products Administration supports the R&amp;D of innovative drugs and devices, promoting leapfrog development in the innovative drug industry. BeiGene, as an innovative drug company, benefits from favorable policies, but the market's short-term reaction is below expectations. Source: Jinwu Finance
On December 12, CMB International pointed out that the dual directory of medical insurance + commercial insurance has been implemented, optimizing the payment system for innovative drugs. BeiGene, as an innovative pharmaceutical company, benefits, but the market has low expectations for short-term sales growth. Source: Jinwu Financial News. Policy support for the innovative drug industry, market volatility intensifies.
</li>
</ol>
Innovent Biologics fell 4.23%. Based on recent key news:
<ol>
<li>
On December 12, Innovent Biologics' stock price fell back from the second-highest point of HKD 99.00, approaching the lower bound of the Bollinger Bands, with shrinking trading volume, indicating limited endurance of the bears. Analysts suggest maintaining a buy-on-dips strategy, as the downside space for the stock price has significantly narrowed. Source: Hong Kong 01
</li>
<li>
On December 12, Innovent Biologics announced that it has launched 17 products, with one new drug application currently under review. This news may affect market expectations for the company's future growth. Source: PR Newswire
</li>
<li>
On December 12, Innovent Biologics plans to initiate the Phase III registration trial of Mazdutide to evaluate its effects in adolescents, aiming to address significant clinical needs. This move may enhance market confidence in the company's R&amp;D capabilities. Source: RTT News. Recent volatility in Hong Kong stocks, with complex capital flows.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Kanglongda Biotech-B fell 8.44%. Based on recent news,
<ol>
<li>
On December 13, Kanglongda's Bodo Trastuzumab won in a head-to-head Phase III clinical study against Roche's HER2 ADC, significantly outperforming competitors, but the third-line indication was not approved, affecting market confidence. Data shows that the median PFS for the Bodo Trastuzumab group reached 11.1 months, significantly better than the 4.4 months for the Enmetuzumab group. Source: Zhito Finance
</li>
<li>
On December 12, CICC maintained a buy rating on Kanglongda with a target price of HKD 550. Nevertheless, the market reacted negatively to the news of its third-line indication not being approved. Source: Zhito Finance
</li>
<li>
On December 14, Hubei Province launched cross-provincial retrieval of medical insurance imaging cloud, although not directly related to Kanglongda, it shows the rapid development and intensifying competition in the medical industry. Source: Wall Street News. Intensifying competition in the medical industry, strict approval for innovative drugs
</li>
</ol>

02592

CLOUDBREAK-B fell 16.79%; KANGFANG BIO fell 6.67%, with a transaction volume of HKD 1.08 billion; BAIDU SHENZHOU fell 7.35%, with a transaction volume of HKD 1.072 billion; SINOPHARM BIOTECH fell 4.23%, with a transaction volume of HKD 958 million; KELUN BOTAIBIO-B fell 8.44%, with a market value of HKD 93.7 billion

Hong Kong Stock Movement: CLOUDBREAK-B fell 16.79%, clinical progress fails to dispel market concerns